Transgenic parasites accelerate drug discovery

Trends in Parasitology

Volumn 28, Issue 3, 2012, Pages 90-92

  Rodriguez, Ana ^a   Tarleton, Rick L ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT;

DRUG DESIGN; HIGH THROUGHPUT SCREENING; HOST CELL; IN VIVO STUDY; LEISHMANIA; NONHUMAN; PARASITE DEVELOPMENT; PARASITE IDENTIFICATION; PARASITOSIS; PLASMODIUM; PROCESS OPTIMIZATION; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; TRANSGENIC ORGANISM; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIPARASITIC AGENTS; DRUG DISCOVERY; MICE; NEGLECTED DISEASES; PARASITES; PROTOZOAN INFECTIONS;

ANIMALIA;

EID: 84857233757     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2011.12.003     Document Type: Review

References (14)

1. Gamo F.J., et al. Thousands of chemical starting points for antimalarial lead identification. Nature 2010, 465:305-310.
2. Guiguemde W.A., et al. Chemical genetics of Plasmodium falciparum. Nature 2010, 465:311-315.
3. Sharlow E.R., et al. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl. Trop. Dis. 2009, 3:e540.
4. Simeonov A., et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis. 2008, 2:e127.
5. Canavaci A.M., et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl. Trop. Dis. 2010, 4:e740.
6. Andriani G., et al. Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl. Trop. Dis. 2011, 5:e1298.
7. Bustamante J.M., Tarleton R.L. Methodological advances in drug discovery for Chagas disease. Expert Opin. Drug Discov. 2011, 6:653-661.
8. Lang T., et al. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell. Microbiol. 2005, 7:383-392.
9. Claes F., et al. Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness. PLoS Negl. Trop. Dis. 2009, 3:e486.
10. Franke-Fayard B., et al. Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. Int. J. Parasitol. 2008, 38:1651-1662.
11. Mwakingwe A., et al. Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. J. Infect. Dis. 2009, 200:1470-1478.
12. Ploemen I.H., et al. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS ONE 2009, 4:e7881.
13. Hyland K.V., et al. Bioluminescent imaging of Trypanosoma cruzi infection. Int. J. Parasitol. 2008, 38:1391-1400.
14. Franke-Fayard B., et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11468-11473.